Swiss Medica Inc., Innovative Products That Improve Peoples' Lives

6/21/2004 12:16:26 PM ET

FOR IMMEDIATE RELEASE

Stock Symbol: OTC BB: SWME

June 21, 2004

SWISS MEDICA ANNOUNCES NEW O24 DESIGN AND PACKAGING BY AWARD-WINNING NEW YORK

ADVERTISING AGENCY TO DEBUT AT MAJOR TRADE SHOW

Toronto, Canada - Grant Johnson, President and COO of Swiss Medica, is pleased to announce the debut of

the O24 Pain Relief product packaging design at the June 21st – 24th NACDS Marketplace (National Association

of Chain Drug Stores) in San Diego, California. This is the world’s largest trade show in the Chain Drug Store

category.

Packaging for the O24 product presents an entirely new look for this patented all-natural pain relief formula. It is

now offered in a one-ounce frosted glass bottle with a pump spray delivery. The Steve Agency of New York City

re-designed the new appearance, tapping upon their award-winning creative expertise in advertising campaigns

for many household brands. These include Budweiser, JP Morgan Chase and L’Oreal.

Grant Johnson said, “We are delighted to launch our newly designed package in time for the NACDS show. This

combined with the appearance of former heavyweight boxing champ Larry Holmes at our booth will make O24

Essential Oil Pain Neutralizer a ‘must see’ product at the NACDS Marketplace. You can visit Swiss Medica at

NACDS Marketplace booth number 914 this week in San Diego.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our

market share through focused distribution strategies in multiple sales channels. Swiss Medica’s mission is to be

a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please

visit our websites at www.swissmedica.com and

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the

United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking

statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close

transactions being contemplated, risks related to international sales and potential foreign currency exchange

fluctuations, continued acceptance of Swiss Medica’s products, increased levels of competition, technological

changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s

periodic reports filed with the United States Securities and Exchange Commission and other regulatory

authorities.

Investor Relations Contact:

Swiss Medica

David Jones

1-866-4

85-4243